The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. BridgeBio Pharma Inc shares valued at $85,000 were sold by Scott Randal W. on Mar 01 ’24. At $34.00 per share, Scott Randal W. sold 2,500 shares. The insider’s holdings dropped to 6,500 shares worth approximately $0.18 million following the completion of this transaction.
Also, Valantine Hannah sold 2,915 shares, netting a total of over 110,041 in proceeds. Following the sale of shares at $37.75 each, the insider now holds 1,764 shares.
Before that, Valantine Hannah had sold 2,915 shares from its account. In a trade valued at $110,683, the Director traded BridgeBio Pharma Inc shares for $37.97 each. Upon closing the transaction, the insider’s holdings decreased to 2,915 shares, worth approximately $48210.119999999995.
Analysts at BMO Capital Markets started covering the stock with ‘”a Market perform”‘ outlook in a report released in late January. As of December 08, 2023, Wells Fargo has initiated its “an Overweight” rating for BBIO. Earlier on December 08, 2023, Wells Fargo initiated its rating. Their recommendation was “an Overweight” for BBIO stock.
Analyzing BBIO Stock Performance
During the last five days, there has been a drop of approximately -6.50%. Over the course of the year, BridgeBio Pharma Inc shares have dropped approximately -32.30%. Shares of the company reached a 52-week high of $41.04 on 02/15/24 and a 52-week low of $26.73 on 04/10/24. A 50-day SMA is recorded $31.67, while a 200-day SMA reached $30.33. Nevertheless, trading volume fell to 1.63 million shares from 1.04 million shares the previous day.
Support And Resistance Levels for BridgeBio Pharma Inc (BBIO)
According to the 24-hour chart, there is a support level at 26.87, which, if violated, would cause prices to drop to 26.41. In the upper region, resistance lies at 27.65. The next price resistance is at 27.97. RSI (Relative Strength Index) is 36.17 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -1.12, which suggests the price will decrease in the coming days. Percent R is at 86.67%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
Is BridgeBio Pharma Inc subject to short interest?
Stocks of BridgeBio Pharma Inc saw a sharp steep in short interest on Mar 15, 2024 dropping by -0.59 million shares to 13.41 million. Data from Yahoo Finance shows that the short interest on Feb 15, 2024 was 14.0 million shares. A decline of -4.4% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.68 of the overall float, the days-to-cover ratio (short ratio) decline to 6.68.
